mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000
View company profile
Please contact the Account Manager for opportunities with this organisation

Genzyme alters the role of its lead independent director

Posted on 08/02/2010 in Pharmaceutical Company Restructures

Genzyme has revealed alterations to the role of its lead independent director and has appointed new leadership for its board's audit committee.

The lead independent director Robert Carpenter, president of Boston Medical Investors, is currently serving in the role of lead director and is also the board chair at Hydra Biosciences.

He will now have a greater role in determining the direction of the discussions that take place at board level - including the approval of full board meeting agendas and materials.

Additionally, a new board director - Robert Bertolini, the former executive vice-president and chief financial officer at Schering-Plough - has been appointed to chair the audit committee.

Connie Mack, a Genzyme board member and chair of the nominating and governance committee, said: "Strengthening the lead independent director position is a growing practice at many companies where chief executive officers also serve as board chair."

Last month, Genzyme revealed that its Pompe disease therapy Lumizyme (alglucosidase alfa) has been granted a six-month review period by the Food and Drug Administration.

Other news stories from 08/02/2010

Read more in the Zenopa News Archive

How this news is generated

Jo-Anne
Account Manager
for this opportunity

01494 818 012
(Mon to Fri 0830 to 1800 hours)
jo@zenopa.com

Latest News

Genzyme foresees future growth following difficult quarter

Genzyme nominates new board member

Genzyme reports growing first quarter biosurgery sales

Genzyme partners with Arecor on protein therapeutics

Genzyme wins recommendation for Mozobil use by NHS Wales

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use